SGD Pharma, a company who provide moulded glass primary packaging solutions for the pharmaceutical industry, announces the fruits of a co-development partnership with Corning: a new range of Type I injectable vials.
SGD Pharma’s vial-converting expertise is combined with Corning’s proprietary glass-coating technology to improve pharmaceutical filling-line productivity and speed the global delivery of injectable treatments.
Defective vials can force production lines to stop and result in recalls, increasing manufacturing costs. SGD Pharma’s new Velocity Vial offering reduces the frictional resistance created by glass-to-glass and glass-to-metal contact, helping pharmaceutical filing lines to prevent potential disruptions to the flow of vials.
This can include tip-overs, jams and glass breakages. As a result, there is a reduction in total cost of ownership and an increase in glass quality, making the fill and finish process 20-50% more efficient.
Vial cracks and glass particle contamination are also a risk to patients, but with SGD Pharma’s Velocity Vials, pharma filling companies will see a reduction in glass particulates of up to 96%.
Because of this, there will be minimal risk of glass particulates getting trapped inside vials during fill and finish operations, protecting the end user and significantly improving product quality and safety.
there is a reduction in total cost of ownership and an increase in glass quality, making the fill and finish process 20-50% more efficient
SGD Pharma’s Type I tubular glass vials are already compliant with USP and EP requirements and are manufactured and released in accordance with ISO GMP standards.
The Velocity Vial coating technology is available in both clear and amber glass, in standard vial sizes 2R to 20R (though sizes up to 30R can be made available on request) and is compliant with EU and US health authorities.
